Author of

• 20182

  +

  P3.03 - Chemotherapy/Targeted Therapy (ID 719)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24073

    +

    P3.03-028 - WINTHER – a Study of Cancer Therapy Based on Tumor and Normal-Matched Biopsies – the Sheba Medical Center Lung Cancer Experience (ID 10383)

    09:30 - 09:30  |  Author(s): A. Ackerstein
    • Abstract

    Background:
    Patient-tailored therapy based on tumor genomics is limited to 30-40% of the patients whose tumor harbor actionable DNA mutations or amplifications.
    
    Method:
    WINTHER is an international open label non-randomized clinical trial developed by the WIN consortium. Matched tumor and normal tissue biopsies are collected and analyzed by NGS (Foundation Medicine) or by functional genomics utilizing a prediction model of efficacy developed at Ben Gurion University.
    
    Result:
    56 patients were biopsied. 29 (52%) had lung cancer. Successful biopsies yielding sufficient material for full genomic analyses were achieved in 29 subjects (53%). Lung biopsy success rates were 71% and 61% respectively for normal and tumor specimens. To date, 11 lung cancer patients were treated with chemotherapy (1) or biologic agents (11). Targeted genomic alterations included EGFR (3), RET (2), KRAS (2), ALK (1), ErbB2 (1), ErbB3 (1), BRAF (1). Clinical benefit rate (CBR) was 55% (6/11) with 1 subject achieving compete response, 2 partial response and 3 stable disease. Response durations were 7, 14 and 18 months.
    
    Conclusion:
    Tumor genomic analysis based on the comparison of matched tumor and normal biopsies is acceptable and feasible. The experience of the multidisciplinary team is an important contributor to the program’s success.